ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular testing solutions, will address the need for access to critical advanced molecular testing, labor shortages that limit the availability of testing, and other obstacles laboratories face in adopting this technology at the American Association for Clinical Chemistry (AACC) Annual Meeting in Chicago, Illinois, July 27-31.
Rheonix will display its Chemical and Reagent Device (CARD) and EncompassMDx™ molecular testing platform. The… Read More »
Food poisoning. The impact on consumers can range from an inconvenient bout of gastrointestinal discomfort to hospitalization or even death. Every year in the U.S., one in six people suffers a food-related illness. Foodborne pathogens were responsible for 3,000 deaths reported in the U.S. in 2013. To help protect consumers, food producers and manufacturers follow rules promulgated by the U.S. Food and Drug Administration (FDA) and test food for pathogens.… Read More »
ITHACA, N.Y. — Rheonix, Inc., a developer of fully automated molecular testing solutions, has received a Small Business Innovation Research (SBIR) Phase I Fast-Track grant from the National Institutes of Health (NIH) to complete the development of a fully automated self-confirming assay that can simultaneously detect HIV/AIDS antibodies and viral RNA in a single specimen. The Rheonix system will simplify HIV testing and eliminate the need for multiple patient visits… Read More »
ITHACA, N.Y. — Richard A. Montagna, Ph.D., senior vice president for scientific and clinical affairs at Rheonix Inc., a developer of fully automated molecular diagnostics solutions, has been accepted as a Fellow of the National Academy of Clinical Biochemistry (NACB).
Fellowship in NACB is open to members of the American Association of Clinical Chemistry (AACC) who are doctoral-level clinical scientists. Fellows must hold American Board of Clinical Chemistry or equivalent board… Read More »
ITHACA, N.Y. – March 24, 2014 - Rheonix, Inc., a developer of fully automated molecular testing solutions, announced today that it has been invited to exhibit at “The Future of In-Vitro Diagnostics.” The exclusive conference, held April 10, 2014 in Menlo Park/Palo Alto, CA, is hosted by Siemens Venture Capital, the investment arm of Siemens, and Siemens Healthcare.
The fifth annual conference brings together over 100 CEOs and CTOs, investors, key… Read More »
ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular diagnostics solutions, has been granted six additional patents for its core microfluidic device, the Chemistry and Reagent Device, or CARD® . One patent was issued Feb. 11, while the other five have been allowed but not yet issued.
The Rheonix CARD is a disposable cartridge the size of a credit card that runs multiple samples simultaneously without user intervention. Once… Read More »
ITHACA, N.Y. — Rheonix, Inc., a developer of fully automated molecular testing solutions, has created a channel-free microfluidic device, the Rheonix Smart FilmCARD™. The Smart FilmCARD would be the first microfluidic device in the diagnostics industry with no channels included in its design, a breakthrough that will significantly decrease the research, development and production costs of microfluidic solutions and allow sophisticated diagnostic tests to become more widely available. The Smart… Read More »
ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular testing solutions, has established the Rheonix Innovation Center to allow the company to continue to develop core technology within its expansive intellectual property portfolio. The center is adjacent to the company’s new headquarters in Ithaca, N.Y.
Employees within the center will be tasked with applying Rheonix’s technical capabilities to solving molecular testing challenges outside the traditional scope of automated molecular… Read More »
ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular testing solutions, raised $14 million in a combination of debt and equity investments to complete a manufacturing build out and launch its first commercial product. The funds will be used to expand the company’s physical operations to produce consumables and systems to fulfill Rheonix’s joint development agreement with Life Technologies Corp. and for the commercialization of its first clinical,… Read More »
With $14 MILLION in debt and equity financing in hand, molecular diagnostics firm Rheonix is planning to expand both its physical footprint and molecular testing product portfolio in the coming year, company president Tony Eisenhut said this week.
First, Rheonix is already in the process of building out new manufacturing facilities just down the street from its current Ithaca, NY, headquarters, primarily to enable it to produce consumables and systems to… Read More »